Literature DB >> 12721319

Prevalence of extended-spectrum beta-lactamase-producing Gram-negative bacteria in septicaemic neonates in a tertiary care hospital.

Amita Jain1, Indranil Roy1, Mahendra K Gupta1, Mala Kumar1, S K Agarwal1.   

Abstract

The present study was undertaken to investigate the high incidence of multiresistant Gram-negative bacilli causing neonatal septicaemia. Samples of neonatal blood from 728 suspected cases were obtained in brain heart infusion broth with sodium polyanethol sulfonate. All Gram-negative rods isolated were subsequently subjected to routine antimicrobial susceptibility testing and tests for extended-spectrum beta-lactamase (ESBL) production, as per NCCLS recommendations. ESBL was detected in 86.6% of Klebsiella spp., 73.4% of Enterobacter spp. and 63.6% of Escherichia coli strains. It was also observed that 74.4-80.9% of these ESBL producers were resistant to cefotaxime and 47.6-59.5% were resistant to ceftazidime in routine susceptibility testing. Some ESBL producers (36.3-61.5%) were found to be susceptible to either or both cephalosporins used in this study. It is concluded that indiscriminate use of third-generation cephalosporins may be responsible for the selection of ESBL-producing multiresistant strains in the neonatal intensive-care unit (NICU).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12721319     DOI: 10.1099/jmm.0.04966-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  32 in total

Review 1.  Unnatural selection: reducing antibiotic resistance in neonatal units.

Authors:  D Isaacs
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2006-01       Impact factor: 5.747

2.  Epidemiology of infections due to extended-spectrum Beta-lactamase-producing bacteria in a pediatric intensive care unit.

Authors:  Kim W Benner; Priya Prabhakaran; Autumn S Lowros
Journal:  J Pediatr Pharmacol Ther       Date:  2014-04

3.  Extended-spectrum-β-lactamase-producing Escherichia coli isolate possessing the Shiga toxin gene (stx1) belonging to the O64 serogroup associated with human disease in India.

Authors:  T K Dutta; Iadarilin Warjri; P Roychoudhury; H Lalzampuia; I Samanta; S N Joardar; S Bandyopadhyay; Rajesh Chandra
Journal:  J Clin Microbiol       Date:  2013-04-10       Impact factor: 5.948

4.  Isolation of MRSA, ESBL and AmpC - β -lactamases from Neonatal Sepsis at a Tertiary Care Hospital.

Authors:  Amutha Chelliah; Ravinder Thyagarajan; Radhika Katragadda; K V Leela; R Narayana Babu
Journal:  J Clin Diagn Res       Date:  2014-06-20

5.  Antimicrobial resistance status and prevalence rates of extended spectrum beta-lactamase (ESBL) producers isolated from a mixed human population.

Authors:  Ruth A Afunwa; Damian C Odimegwu; Romanus I Iroha; Charles O Esimone
Journal:  Bosn J Basic Med Sci       Date:  2011-05       Impact factor: 3.363

6.  Detection of the SHV genotype polymorphism of the extended-spectrum β-lactamase-producing Gram-negative bacterium.

Authors:  Junlong Li; Xiaoli Ji; Xiaohui Deng; Yingfeng Zhou; Xiaoqing Ni; Xiaokang Liu
Journal:  Biomed Rep       Date:  2015-01-07

7.  Predictors of positive blood culture and deaths among neonates with suspected neonatal sepsis in a tertiary hospital, Mwanza-Tanzania.

Authors:  Neema Kayange; Erasmus Kamugisha; Damas L Mwizamholya; Seni Jeremiah; Stephen E Mshana
Journal:  BMC Pediatr       Date:  2010-06-04       Impact factor: 2.125

8.  First Report of OXA-4, an ESBL Isolated from Pseudomonas aeruginosa a South Indian Strain.

Authors:  S A Jemima Kingsley; Susan Verghese
Journal:  Indian J Microbiol       Date:  2012-10-31       Impact factor: 2.461

9.  The aetiology of the bloodstream infections in the patients who presented to a tertiary care teaching hospital in kathmandu, Nepal.

Authors:  Santwana Pandey; Shahid Raza; Chandra Prakash Bhatta
Journal:  J Clin Diagn Res       Date:  2013-04-01

10.  Extended spectrum beta lactamase producing Klebsiella pneumoniae in neonatal intensive care unit.

Authors:  B V S Krishna; Asha B Patil; M R Chandrasekhar
Journal:  Indian J Pediatr       Date:  2007-07       Impact factor: 1.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.